Novel daratumumab-based regimen slows multiple myeloma progression

Bookmark and Share
Published: 5 Jun 2016
Views: 1810
Prof Antonio Palumbo - University of Torina, Turin, Italy

Prof Palumbo presents at ASCO 2016, initial findings from a pivotal phase III trial that showed that daratumumab added to a standard two-drug regimen (bortezomib and dexamethasone) markedly improved outcomes for patients with recurrent or refractory multiple myeloma.

Read the news story and watch the video interview for more.